XRAY

Dentsply Sirona is the world's largest dental-products maker, yet the numbers describe a business in structural decline, not a temporary stumble. Revenue has fallen every single year since 2021 — $4.23B → $3.92B → $3.96B → $3.79B → $3.68B (FY2025 -3.0%, and -4.3% on a constant-currency basis per the MD&A, with the reported figure flattered ~1.3% by a weaker dollar). This is the fifth consecutive year of net losses outside 2021, and the company has now taken goodwill/intangible impairments in three of the last four years ($1,014M in FY2024, $650M in FY2025). Those write-downs are management repeatedly admitting it overpaid for assets that aren't earning their keep — retained earnings have swung to -$1.56B and stockholders' equity collapsed 31% in a year to $1.34B.

The bull case is that the FY2025 loss is mostly non-cash: strip the $650M impairment and the business is roughly breakeven, gross margin is a healthy 50%, and operating cash flow was still positive at $235M. But that cash story is also deteriorating — OCF fell 49% YoY, and after $131M of capex, free cash flow of ~$104M does not even cover the $128M dividend. The gap is being plugged with debt: long-term debt rose 27% to $2.02B and the current portion jumped 78% to $228M, pushing liabilities/equity to a stretched 3.05x against just $326M of cash. A company paying an uncovered dividend while levering up into a revenue decline is borrowing to maintain appearances.